Extremely important positive changes in investment behavior have recently occurred for ADMA Biologics Inc (NASDAQ: ADMA): the stock rose on very heavy volume, and positive upside/downside volume developed.
ADMA Biologics Inc (NASDAQ: ADMA). Significant positive changes in fundamentals have recently occurred: the consensus estimate for December, 2025 increased significantly, and the consensus estimate for December, 2024 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, ADMA is expected to be a major Value Builder.
ADMA Biologics has a current Value Trend Rating of B (Positive). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. ADMA Biologics has a slightly negative Appreciation Score of 39 but a very high Power Rating of 95, triggering the Positive Value Trend Rating.
Recent Price Action
ADMA Biologics Inc (NASDAQ: ADMA) stock enjoyed a large increase of 2.7% on 6/21/24. The stock closed at $11.00. Moreover, exceptionally high trading volume at 257% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 2.0% during the last week.
Be the first to comment